- The European Commission (EC) had agreed with BioNTech SE BNTX And Pfizer Inc PFE on the adjustment of the existing contract on vaccines against Covid-19, including a reduction in the amount of doses purchased by EU countries under the contract and a postponement of the delivery date to 2026.
- “The change to the existing vaccine supply agreement reflects the improved epidemiological situation while continuing to ensure access to the latest available version of the vaccine should any Covid-19 variants of concern arise in the future,” the said EC called.
- Related: European Union’s amended COVID-19 vaccine deal with Pfizer-BioNTech: near-monopoly status poses potential threat to competitors.
- The agreement provides for a reduction in the number of cans purchased by Member States under the agreement.
- After paying a fee, originally agreed doses are converted into optional orders.
- The deal also provides for an extension of the period during which EU countries can receive the vaccines – up to four years.
- The agreement allows access to additional doses up to the originally contracted amount until the end of the contract to meet the needs if cases increase and the epidemiological situation worsens.
- The original deal, signed in May 2021, committed the EU to purchase 900 million doses from Pfizer/BioNTech, with an option for an additional 900 million. until the end of 2023.
- However, due to lower demand over the past year, about half or more of the original 900 million doses under the contract have yet to be delivered. The EU has not exercised the option for additional doses.
- Photo via Wikimedia Commons
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
[ad_2]
Source story
